The Spring Scientific is almost here and will take place on March 12–14, 2025. #SITC will bring the brightest minds and next generation of leaders together to explore promising #science and develop novel opportunities to address these challenges. Register: go.sitcancer.org/4fupoc0

#ScienceSaturday ❓ Are B cells important to eliminate cancers? T cells, capable of directly killing cancers, have been widely studied in tumor immunology. ➡️ B cells, which produce antibodies, are important to prevent infections and are now being studied for their role in

Dear Trainees, bookmark this👇 Dr. Marco Ruella Society for Immunotherapy of Cancer teaching us how to give a good talk, by purposefully giving a *bad* talk! 👏😉 - Lighter the better - Less is more - Consistent font - Large font size (>=18) - Careful with animations: friends sometimes (to help introduce

It was a happy task, being asked to reflect on the contributions of the Branch. Humbly standing on the shoulders of giants, creating the medicines of tomorrow. TIL immunotherapy comes of age: a journey of development in the Surgery Branch, NCI jitc.bmj.com/content/13/4/e…

Kicking off our keynote speaker series at #MoffittBoB today Moffitt Cancer Center. Thank you to our first keynote, Craig Maxwell, Senior Vice President, Head of Oncology R&D Strategy, Business Development & Academic Research Partnerships AstraZeneca, who is discussing fostering

Thrilled to share our latest study just out in nature 😄A major milestone in our collaboration with ⁦Anirban Maitra⁩ Led by brilliant ⁦⁦⁦Guangsheng Pei⁩ ⁦⁦⁦⁦⁦⁦⁦⁦⁦⁦⁦Jimin Min⁩ ⁦⁦MD Anderson Cancer Center⁩ nature.com/articles/s4158…

Onsite access to the full slate of Professional Development Series of Sessions taking place at the AACR Annual Meeting 2025 are available to registered AACR members at no additional cost. aacr.org/professionals/…

Amazing #AACR25 special evening Town Meeting "How AI Will Impact the Future of Pathology"! hosted by Dr. Massimo Loda. Featuring foundation models, agentic AI, benchmarking, multimodal data and drug development! Faisal Mahmood, Jelle Wesseling, Kenneth Bloom & Jorge S. Reis-Filho

My strongest support for Dr. Tina Cascone MD PhD who has been nominated for the Society for Immunotherapy of Cancer board of directors election! She is a truly outstanding physician scientist, generous collaborator, leader in SITC and great human being! Please vote! sitcancer.org/membership/202…

Yesterday, we joined AstraZenecaUS to celebrate a $300 million investment in their new cell therapy facility in Montgomery County —bringing 150 high-skilled jobs & new hope in the fight against cancer. It was great to be joined by the entire District 15 team Senator

Regulating the fate of tumor-associated macrophages cell.com/cancer-cell/ab…

One final thing. Harvard has launched an incredible effort to share the impact of the funding cuts with the public on their website landing page. We need more like this: harvard.edu

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get this powerful therapy to more people go.nature.com/3HdT8O1

Out now & open access in Nature Medicine concurrent with presentation at #ASCO2025 is NeoCOAST-2! I have been delighted to collaborate on the first platform neoadjuvant trial in lung cancer led by Dr. Tina Cascone nature.com/articles/s4159… ! #LCSM 1/6

I’ve been in the exercise oncology field for 20 years and for all of that time, the main criticism has been “show me a well controlled RCT.” Well, here it is. Exercise following adjuvant chemotherapy for colon cancer reduced recurrence and improves OVERALL SURVIVAL! #ASCO25

Delighted to share our new approach to enhance CAR T cell function in solid tumours published today nature. In this work we identify a new strategy to generate armoured CAR T cells. nature.com/articles/s4158…

Final COMPASS trial data advanced #PDAC ➡️268 WGS& 253RNA-seq ➡️basal-like& hi GRIm-S ⬇️OS, both unique TME inc CD8 variation,NB primaries vs mets ➡️LTS :HRD, KRAS WT ➡️KRAS major enriches basal, >type II DM ➡️LAPC≠intact SMAD4 ➡️47% receive 2nd line tx nature.com/articles/s4146…

Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial in JAMA Network Open AstraZeneca

Our manuscript using single cell RNA sequencing to compare two CD19 CAR T cell products, axi-cel and tisa-cel is online at JITC! Frederick L. Locke Moffitt Cancer Center jitc.bmj.com/content/13/7/e… . Our findings (thread):

I am thrilled to finally share my lab's first paper showing that sucralose consumption reduces immunotherapy efficacy in cancer, published NOW in Cancer Discovery ! Let's break it down. 1/n aacrjournals.org/cancerdiscover…